Skip to main content
main-content

Diabetes

Latest articles

23-09-2019 | Diabetes | News | Article

RISE compares alpha, beta cells in youth vs adults with early type 2 diabetes

The failure of intensive medication to halt beta-cell decline in children with early type 2 diabetes occurs despite them having better baseline beta-cell and alpha-cell function than newly diagnosed adults, say the RISE researchers.

23-09-2019 | Diabetes | News | Article

Add-on liraglutide may preserve insulin secretion in type 1 diabetes

Findings from the NewLira trial suggest that addition of the glucagon-like peptide-1 receptor agonist liraglutide to insulin treatment may preserve postprandial insulin secretion among adults with newly diagnosed type 1 diabetes.

20-09-2019 | Diabetes | News | Article

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

19-09-2019 | Rheumatology | News | Article

IL-1 inhibition may benefit people with RA, type 2 diabetes

Treatment with the interleukin-1 inhibitor anakinra improves both glycemic and inflammatory endpoints among patients with rheumatoid arthritis and type 2 diabetes, suggest findings from the TRACK trial.

19-09-2019 | Diabetes | News | Article

Imeglimin shows promise for type 2 diabetes

Imeglimin, an agent that improves mitochondrial function, has demonstrated potential as a novel treatment option for Japanese patients with type 2 diabetes in the phase III TIMES 1 and TIMES 3 trials.

18-09-2019 | Diabetes | News | Article

Semaglutide tops liraglutide in SUSTAIN 10

Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.

18-09-2019 | Diabetes | News | Article

SUSTAIN 8: Semaglutide outperforms canagliflozin as second-line therapy for type 2 diabetes

Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.

18-09-2019 | Diabetes | News | Article

Trial results VERIFY first-line combination therapy for type 2 diabetes

Upfront combination therapy with vildagliptin and metformin is more durable than metformin alone, and appears to have a legacy effect, report the VERIFY investigators.

18-09-2019 | Diabetes | News | Article

Type 2 diabetes genetic liability manifests in early lipid changes

Genetic liability to type 2 diabetes manifests in altered lipid profiles from as early as 8 years of age, say researchers.

18-09-2019 | Diabetes | News | Article

Trial shortcomings make GABA benefits unclear in early type 1 diabetes

The limitations of a clinical trial of gamma aminobutyric acid on the progression of newly diagnosed type 1 diabetes may have precluded any positive results, say the researchers.

18-09-2019 | Diabetes | News | Article

Collaborative type 2 diabetes care model has lasting benefits

Ten-year results from the Beijing Community Diabetes Study indicate that collaborative care delivered by primary care providers and specialists may result in sustained improvements in cardiovascular risk factor control among people with type 2 diabetes.

17-09-2019 | Diabetes | News | Article

PIONEER data support oral semaglutide across a wide range of patients

Researchers at the 55th EASD Annual Meeting in Barcelona, Spain, have presented primary data and subanalyses from a number of the PIONEER trials investigating the efficacy of oral semaglutide in people with type 2 diabetes.

17-09-2019 | Diabetes | News | Article

Suboptimal glycemic control shown in adults with type 1 diabetes

Results of the SAGE study demonstrate suboptimal glycemic control among adults of all ages with type 1 diabetes across the globe.

17-09-2019 | Diabetes | News | Article

CGM benefits persist with long-term use

The COMISAIR-2 researchers have reported that use of continuous glucose monitoring by people with type 1 diabetes remains high over 3 years, resulting in continued glycemic benefits.

16-09-2019 | Diabetes | News | Article

Diabetes incidence may be falling in many countries

A systematic review in The BMJ suggests the incidence of diabetes may be falling in many countries, with researchers suggesting preventive strategies may be proving effective.

16-09-2019 | Diabetes | News | Article

DEFINE-HF: Further support for add-on dapagliflozin as a treatment option for heart failure

Results of the DEFINE-HF trial indicate that add-on dapagliflozin treatment may improve health status among people with established heart failure and reduced ejection fraction.

13-09-2019 | Diabetes | Main feed | News

Prescription records best clinical indicator of future diabetes medication adherence

Adherence to first-line diabetes medication, ascertained from prescription records, is the only routine clinical variable that is a strong indicator of people’s adherence to second-line treatment, say researchers.

12-09-2019 | Diabetes | News | Article

Strength, balance training benefits people with diabetic peripheral neuropathy

Short-term structured strength and balance training does not improve quality of life in patients with type 2 diabetes-related peripheral neuropathy, but may increase functional status and balance confidence, research shows.

11-09-2019 | Diabetes | News | Article

Diabetes linked to increased frailty during aging

Older people with diabetes are frailer throughout aging than those without diabetes, study findings indicate.

10-09-2019 | Diabetes | News | Article

Type 1 diabetes severe hypoglycemia predictors identified in HypoCOMPaSS analysis

Researchers have identified factors that predict repeated very low blood sugar among adults with type 1 diabetes who have suboptimal awareness of hypoglycemia.